Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Mar 19, 2035method-of-use (U-1854)US 10272058
Mar 19, 2035method-of-use (U-1854)US 11406611
Mar 19, 2035method-of-use (U-1854)US 11596614
Mar 19, 2035method-of-use (U-1854)US 9486428
Sep 13, 2026compositionUS 7709682
Aug 2, 2026compositionUS 7301050

FDA exclusivities (2)

Aug 14, 2031ODE-486Orphan Drug (7y)4.9y
Aug 14, 2029NCENew Chemical Entity (5y)2.9y

News(1)

CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…
fiercebiotech · 19d ago

brand

Livdelzi

generic

seladelpar lysine

MOA

12.1 Mechanism of Action Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. However, the mechanism by which seladelpar exerts its therapeutic effects in patients with PBC is not well understood. Pharmacological activity that is potentially relevant to therapeutic effects includes inhibition of bile acid synthesis through activation of PPARδ, which is a nuclear receptor expressed in most tissues, including the liver. Published studies show that PPARδ activation by seladelpar reduces bile acid synthesis through Fibroblast Growth Factor 21 (FGF21)-dependent downregulation of CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol.

indication

Primary Biliary Cholangitis (Primary Biliary Cirrhosis)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 9m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(1)

CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…

fiercebiotech · 19d ago

seladelpar lysine

🐶 often sniffed alongside

all catalysts(2)

Patent cliff

patents (6)

FDA exclusivities (2)

News(1)

Report a data issue

comments(0)

seladelpar lysine

🐶 often sniffed alongside

all catalysts(2)

Patent cliff

patents (6)

FDA exclusivities (2)

News(1)

Report a data issue

comments(0)